However, when target cells were pre-incubated with 10 μg/ml of their respective antibodies, the CD16+ monocytes lysed between 10% and 40% of the cells, depending on the E:T ratio and cancer cell line used (Fig. 1A–C; left panels solid lines). This evidence concerns the gene FCGR3A and cancer.